APA

Palmer A. J., Annemans L., Roze S., Lapuerta P., Chen R., Gabriel S., Carita P., Rodby R. A., de Zeeuw D., Parving H. & De Alvaro F. (20050608). Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. : Kidney international. Supplement.

Chicago

Palmer Andrew J, Annemans Lieven, Roze Stéphane, Lapuerta Pablo, Chen Roland, Gabriel Sylvie, Carita Paulo, Rodby Roger A, de Zeeuw Dick, Parving Hans-Henrik and De Alvaro Fernando. 20050608. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. : Kidney international. Supplement.

Harvard

Palmer A. J., Annemans L., Roze S., Lapuerta P., Chen R., Gabriel S., Carita P., Rodby R. A., de Zeeuw D., Parving H. and De Alvaro F. (20050608). Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. : Kidney international. Supplement.

MLA

Palmer Andrew J, Annemans Lieven, Roze Stéphane, Lapuerta Pablo, Chen Roland, Gabriel Sylvie, Carita Paulo, Rodby Roger A, de Zeeuw Dick, Parving Hans-Henrik and De Alvaro Fernando. Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. : Kidney international. Supplement. 20050608.